PanCAD.ai Co., Ltd. is a spin-off startup of National Taiwan University and National Taiwan University Hospital. Guided by the philosophy of "unity is strength," the company integrates the forces of industry, academia, research, and medicine, focusing on the global smart healthcare market. With a long-term commitment to the research and development of intelligent analysis for abdominal medical imaging, PanCAD.ai assists physicians and the public in improving medical outcomes.

By assisting medical diagnosis with artificial intelligence and implementing technology in clinical practice, the company addresses disease risks that are difficult for the human eye to distinguish. When technology and medicine join hands, they can secure more chances of survival for patients, turning every early detection into an opportunity to transform lives.

PanCAD.ai begins with pancreatic cancer, as it is clinically one of the most difficult cancers to detect and combat. However, PanCAD.ai's goal is not limited to a single disease, but rather to capture every opportunity where detection is still possible in time. PanCAD.ai hopes to accompany physicians in identifying lesions that were previously difficult to detect, and to support patients in gaining greater confidence during the golden window of treatment. By making difficult diseases no longer elusive, PanCAD.ai aims to bring Taiwan's smart healthcare to the global stage and change the fate of patients worldwide.